ArticleFilaria journal2003
Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis.
Article in Filaria journal, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 48 citations in OpenAlex.
- Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule.International journal for parasitology. Drugs and drug resistance · 2015Trial
- Doxycycline Leads to Sterility and Enhanced Killing of Female Onchocerca volvulus Worms in an Area With Persistent Microfilaridermia After Repeated Ivermectin Treatment: A Randomized, Placebo-Controlled, Double-Blind Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Trial
- A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.PLoS neglected tropical diseases · 2014Trial
- Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study.Medical microbiology and immunology · 2008Trial
- Onchocerciasis overview: pathogenesis, clinical spectrum, and therapeutic challenges of a neglected tropical disease.Frontiers in parasitology · 2026Review
- Eosinophils in filarial infections: Inducers of protection or pathology?Frontiers in immunology · 2022Review
- Filaricidal activity of Daniellia oliveri and Psorospermum febrifugum extracts.Parasites & vectors · 2021Article
- Assembling Pharma Resources to Tackle Diseases of Underserved Populations.ACS medicinal chemistry letters · 2020Article
- Identification of Ecdysone Hormone Receptor Agonists as a Therapeutic Approach for Treating Filarial Infections.PLoS neglected tropical diseases · 2016Article
- Phenotypic and molecular analysis of the effect of 20-hydroxyecdysone on the human filarial parasite Brugia malayi.International journal for parasitology · 2016Article
- Situation analysis of parasitological and entomological indices of onchocerciasis transmission in three drainage basins of the rain forest of South West Cameroon after a decade of ivermectin treatment.Parasites & vectors · 2015Article
- A murine macrofilaricide pre-clinical screening model for onchocerciasis and lymphatic filariasis.Parasites & vectors · 2014Article
- Nodding syndrome in Mundri county, South Sudan: environmental, nutritional and infectious factors.African health sciences · 2013Article
- Validation of a remote sensing model to identify Simulium damnosum s.l. breeding sites in Sub-Saharan Africa.PLoS neglected tropical diseases · 2013Article
- Identification of genes containing ecdysone response elements in the genome of Brugia malayi.Molecular and biochemical parasitology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ivermectin (Mectizan(R)) is the only drug currently recommended for the treatment and control of onchocerciasis. Serious adverse events rarely occur during treatment, except in subjects heavily infected with Loa Loa. This review of drug-related serious adverse events in the treatment of onchocerciasis therefore revisited the pre-Mectizan(R) reference drugs, DEC and suramin, and other candidate drugs studied extensively for the treatment of human onchocerciasis. The benzimidazole carbamate derivatives and the antibiotic doxycycline were excluded, since no serious adverse events have been reported regarding their use. Using recommended definitions, serious adverse events reported or observed after the use of each drug were summarised, the level of attribution determined, and the results tabulated. Prominence was given to treatment-related deaths. The clinical picture of severe symptomatic postural hypotension is described and used to illustrate the difference between the severity and the seriousness of an adverse event. The epidemiology, management and outcome of serious adverse events are presented. The role of future research is discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.